These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29899063)

  • 61. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.
    Akeno N; Miller AL; Ma X; Wikenheiser-Brokamp KA
    Oncogene; 2015 Jan; 34(5):589-99. PubMed ID: 24469052
    [TBL] [Abstract][Full Text] [Related]  

  • 62. RSK activation via ERK modulates human colon cancer cells response to PTHrP.
    Calvo N; Carriere P; Martin MJ; Gentili C
    J Mol Endocrinol; 2017 Jul; 59(1):13-27. PubMed ID: 28385776
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mutant p53 gain-of-function in cancer.
    Oren M; Rotter V
    Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
    Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The p53 gene and protein in 2005: new results, promising opportunities].
    Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
    Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular characterization of the cyclin-dependent protein kinase 6 in whitefish (Coregonus lavaretus) and its potential interplay with miR-34a.
    Łakomiak A; Brzuzan P; Jakimiuk E; Florczyk M; Woźny M
    Gene; 2019 May; 699():115-124. PubMed ID: 30858134
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.
    Tigan AS; Bellutti F; Kollmann K; Tebb G; Sexl V
    Oncogene; 2016 Jun; 35(24):3083-91. PubMed ID: 26500059
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.
    Damo LA; Snyder PW; Franklin DS
    Mol Carcinog; 2005 Feb; 42(2):109-20. PubMed ID: 15584024
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Knockdown of lncRNA DLEU1 inhibits the tumorigenesis of oral squamous cell carcinoma via regulation of miR‑149‑5p/CDK6 axis.
    Lv T; Liu H; Wu Y; Huang W
    Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880596
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Pezcoller lecture: cancer cell cycles revisited.
    Sherr CJ
    Cancer Res; 2000 Jul; 60(14):3689-95. PubMed ID: 10919634
    [TBL] [Abstract][Full Text] [Related]  

  • 71. c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
    Kollmann K; Heller G; Ott RG; Scheicher R; Zebedin-Brandl E; Schneckenleithner C; Simma O; Warsch W; Eckelhart E; Hoelbl A; Bilban M; Zöchbauer-Müller S; Malumbres M; Sexl V
    Blood; 2011 Apr; 117(15):4065-75. PubMed ID: 21300982
    [TBL] [Abstract][Full Text] [Related]  

  • 72. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
    Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
    Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.
    Eischen CM; Boyd K
    PLoS One; 2012; 7(9):e46148. PubMed ID: 23029416
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells.
    Gu JF; Liu SG; Pan Q; Qin F; Li YY
    Anat Rec (Hoboken); 2020 Nov; 303(11):2811-2820. PubMed ID: 31916689
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.
    Laman H; Funes JM; Ye H; Henderson S; Galinanes-Garcia L; Hara E; Knowles P; McDonald N; Boshoff C
    EMBO J; 2005 Sep; 24(17):3104-16. PubMed ID: 16096642
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA.
    Niu G; Hellmuth I; Flisikowska T; Pausch H; Rieblinger B; Carrapeiro A; Schade B; Böhm B; Kappe E; Fischer K; Klinger B; Steiger K; Burgkart R; Bourdon JC; Saur D; Kind A; Schnieke A; Flisikowski K
    Oncogene; 2021 Mar; 40(10):1896-1908. PubMed ID: 33603167
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Study on the mechanism of miR-497-induced laryngeal squamous cell carcinoma growth inhibition by targeting CDK6].
    Niu JT; Liu SG; Yan P; Li C
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 54(2):126-132. PubMed ID: 30776865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.